4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

NCTID	NCT06864988 (View at clinicaltrials.gov)
Description	A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (Show More)
Development Status	Active
Indication	Macular Neovascularization Secondary to Age-Related Macular Degeneration
Disease Ontology Term
Compound Name	4D-150
Sponsor	4D Molecular Therapeutics
Funder Type	Industry
Recruitment Status	Recruiting
Enrollment Count	400
Results Posted	Not Available

Target Gene/Variant	Anti-VEGF
Therapy Type	Gene transfer
Therapy Route	In-vivo
Mechanism of Action	Genetic delivery of therapeutic protein
Route of Administration	Intravitreal
Drug Product Type	Viral vector
Target Tissue/Cell
Delivery System	Viral transduction
Vector Type	AAV
Editor Type	none
Dose 1	1E10 vg/eye
Dose 2	3E10 vg/eye (planned phase 3 dose)
Dose 3
Dose 4
Dose 5

No.of Trial Sites	96
Locations	Canada,Puerto Rico,United States

Has US IND	True
FDA Designations	Regenerative Medicine Advanced Therapy
Recent Updates	Phase III trial to begin Q1 2025